Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience
Another Boost For AI
Executive Summary
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.
You may also be interested in...
Amgen Joins AI/ML Gold Rush With Generate Deal
Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target
AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.